Eight-Week Sofosbuvir-Velpatasvir Matches Twelve-Week Course in Non-Cirrhotic Hepatitis C
Trial shows 8-week treatment works for Hepatitis C
In 880 treatment-naive adults with non-cirrhotic hepatitis C, 8 weeks of sofosbuvir-velpatasvir achieved SVR12 rates similar to the standard…
A shorter 8-week course of sofosbuvir and velpatasvir showed similar success rates to the standard 12-week treatment for Hepatitis C patient…
Direct-acting antiviral therapy and diverse viral infections require comprehensive epidemiological and diagnostic strategy review
Review Outlines Treatment and Prevention for Various Viral Infections
This systematic review covers the molecular biology, epidemiology, and treatment strategies for various viral infections including Hepatitis…
A comprehensive review outlines the biological traits, diagnosis methods, and treatment strategies for several common viral infections inclu…
Host non-coding RNAs orchestrate antiviral defense and are targeted by viral counter-defense strategies
Host molecules may help the body fight off common viruses
This systematic review examines how host non-coding RNAs, including miRNAs, lncRNAs, circRNAs, and vtRNAs, modulate antiviral responses agai…
Your body uses special molecules called non-coding RNAs to fight off viruses like flu, Zika, and COVID-19 by blocking their growth.
Incarceration acts as a structural determinant of health with higher rates of chronic and infectious diseases
Incarceration Linked to Higher Rates of Mental Illness and HIV
This narrative review of 167 articles examines the health status and care utilization of incarcerated adults in Canada. It finds significant…
People in correctional centers face higher rates of mental illness and chronic diseases compared to those living in the community.
Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer
Comparing the risks of liver cancer from hepatitis versus lung cancer from smoking
This meta-analysis of 86,097,714 participants analyzed the relative risks of liver cancer from various exposures compared to lung cancer fro…
New data shows that certain hepatitis viruses pose a much higher risk for liver cancer than smoking does for lung cancer.
Major HCV genotypes G1, G2, and G3 account for 98.02% of infections in FSU regions
Analysis Reveals Hepatitis C Genotype Patterns in Former Soviet Union
This scoping review and genotype meta-analysis analyzes HCV genotype distribution and resistance-associated substitutions (RAS) in the Forme…
New data maps the distribution of Hepatitis C genotypes and resistance mutations across the Former Soviet Union to help improve regional mon…
Direct-acting antivirals achieve 89% sustained virologic response in patients with hepatocellular carcinoma and HCV
Direct-acting antivirals show promise for patients with liver cancer
This meta-analysis of 8,839 patients with hepatocellular carcinoma (HCC) and Hepatitis C virus infection found that direct-acting antivirals…
New data suggests that direct-acting antiviral drugs may improve survival and reduce cancer recurrence for people with Hepatitis C and liver…
Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
Green tea compound shows potential for several digestive diseases
This meta-analysis of 63 preclinical studies involving 738 animals indicates that Epigallocatechin-3-gallate (EGCG) has a positive therapeut…
A review of animal studies suggests a green tea compound could help treat various cancers and digestive conditions.
HLA-B*57:01-guided abacavir prescribing is the clearest preventive paradigm from HLA associations
HLA genes shape HIV and hepatitis vaccine responses and drug reactions
This narrative review examines HLA polymorphisms in HIV, hepatitis C, and hepatitis B. The clearest preventive paradigm is HLA-B*57:01-guide…
A review finds that HLA genes strongly influence how people respond to HIV and hepatitis vaccines and how they react to certain medications.
Chronic HCV infection drives T cell dysfunction, regulatory T cell accumulation, and metabolic defects that persist after viral clearance
Immune defects in hepatitis C may last after the virus is gone
This narrative review examines immune mechanisms in patients with chronic hepatitis C virus infection. The authors describe how prolonged an…
A review explains how chronic hepatitis C causes lasting immune changes that persist even after the virus is cleared, suggesting new treatme…
One in six blood donors in Cameroon carries Plasmodium infection, meta-analysis finds
1 in 6 blood donors in Cameroon carries malaria parasite
A systematic review and meta-analysis of 18 studies (~12,500 donations) found a 16.6% pooled prevalence of Plasmodium spp. in Cameroonian bl…
A review of 18 studies finds 16.6% of blood donations in Cameroon contain Plasmodium, the malaria parasite.
Narrative review on ICIs in patients with viral infections and solid tumors
Cancer Immunotherapy Works Differently in Viral Infections
This narrative review synthesizes evidence on immune checkpoint inhibitors in patients with viral infections and solid tumors.
Cancer immunotherapy can still work—and sometimes even control viruses like hepatitis or HIV—but doctors must watch for dangerous flare-ups.
Research across Hepatitis
Related studies from across the Hepatitis family.
HBeAg positivity and high HBV DNA levels increase postpartum ALT elevation risk in chronic hepatitis B
Risk Factors for Liver Inflammation in Mothers with Hepatitis B
This meta-analysis of cohort studies identifies key risk factors for postpartum alanine aminotransferase (ALT) elevation in women with chron…
Specific factors like HBeAg positivity and high viral DNA levels can increase the risk of liver inflammation in women with chronic hepatitis…
HBsAg prevalence 7.0% in dialysis patients, with low HBV-DNA and suboptimal vaccination
Hepatitis B infection rates among patients on dialysis
This meta-analysis of 79 articles estimates hepatitis B burden in dialysis patients globally. Pooled HBsAg prevalence was 7.0% (95% CI 6.1-8…
New data shows that about 7% of patients on dialysis have Hepatitis B, highlighting the need for safer procedures and better vaccination rat…
Community health workers support infectious disease management and PrEP navigation in agricultural communities
Community health workers help farm workers manage infectious diseases
This mini-review examines the role of community health workers (CHWs) in managing infectious diseases among California agricultural workers.…
Community health workers can help farm workers manage serious infections like HIV, tuberculosis, and hepatitis through direct outreach and n…
Hepatic macrophage metabolic reprogramming and bidirectional signaling dictate the balance between liver injury and regeneration
New research identifies how liver cells communicate during chronic disease
This systematic review synthesizes the role of hepatic macrophages in metabolic dysfunction-associated steatotic liver disease, alcohol-asso…
New research reveals how specific immune cells in the liver switch between causing inflammation and repairing tissue damage.
Tonsillar metastasis in hepatocellular carcinoma patients may present as undifferentiated carcinoma with specific IHC markers
Lenvatinib and Chemoembolization Treatment Linked to Liver Cancer Metastasis
This case report and literature review describes a single patient with hepatocellular carcinoma and chronic hepatitis B presenting with a to…
A rare case of liver cancer spreading to the tonsils highlights the need for careful monitoring of head and neck symptoms in patients with l…
Global HBsAg prevalence 3.2% in nurses, with 5.6% in Africa and 3.6% in LMICs
Nurses Face Higher Hepatitis B Risk in Poorer Countries
This meta-analysis estimates global hepatitis B surface antigen (HBsAg) prevalence among hospital-based nurses at 3.2% (95% CI 2.3-4.4), wit…
A global analysis finds 3.2% of hospital nurses carry hepatitis B, with rates four times higher in poorer countries.
Peg-interferon add-on to nucleoside analogues achieves HBsAg loss in 8.6% of patients
Adding peg-interferon to standard treatment helps some hepatitis B patients
This meta-analysis of 581 patients with chronic hepatitis B evaluates peg-interferon add-on to nucleoside analogue therapy. The analysis fou…
Adding peg-interferon to standard nucleoside therapy can help some patients with chronic hepatitis B achieve a key milestone in their treatm…
TZ84-based hepatitis A vaccine shows higher seroconversion rates and GMCs than HM175-based vaccine
TZ84 vaccine shows stronger long-term protection against hepatitis A
This meta-analysis of 3,282 children and adolescents found that the TZ84-based hepatitis A vaccine is associated with higher seroconversion …
One type of hepatitis A vaccine shows higher antibody levels and longer protection in children compared to another common vaccine type.
HBsAg prevalence 9.98% in Cameroon, higher-risk groups 12.70%
New data reveals high rates of Hepatitis B in Cameroon
This meta-analysis of 100 studies estimates HBsAg prevalence at 9.98% in Cameroon, with lower-risk populations at 8.94% and higher-risk at 1…
Nearly 10 percent of people in Cameroon test positive for Hepatitis B, with higher rates found in certain high-risk groups.
Immune markers correlate with clinical outcomes following nucleos(t)ide analogue withdrawal in chronic hepatitis B
Immune Markers May Predict Outcomes After Hepatitis B Treatment
This mini review synthesizes immune correlates of outcome after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. Bene…
New research identifies specific immune markers that may help predict how patients respond when stopping nucleoside analogue medications for…
Bidirectional virus-metabolism interaction in chronic hepatitis B and metabolic dysfunction-associated fatty liver disease
Liver disease and hepatitis B may fuel each other
This systematic review examines the interplay between viral infection and metabolic factors in patients with chronic hepatitis B and metabol…
Hepatitis B and fatty liver disease may worsen each other, raising liver cancer risk. New review explains the link.
Elevated serum M2BPGi is associated with a 4.61 hazard ratio for hepatocellular carcinoma development
Elevated M2BPGi Levels Linked to Higher Risk of Liver Cancer
This systematic review and meta-analysis of 12,161 participants found that elevated serum M2BPGi is significantly associated with an increas…
A large review of over 12,000 patients found that high levels of a specific protein may signal an increased risk for liver cancer.
Questions about Hepatitis C
How should healthcare workers follow up after an acute Hepatitis C Virus infection?
Healthcare workers with acute HCV should undergo baseline and serial HCV RNA testing, with follow-up for at least 6 months to confirm clearance or initiate treatment.
Full answer →Why is the CDC recommending universal screening for Hepatitis C for pregnant women?
The CDC recommends universal Hepatitis C screening for all pregnant women because infection rates have doubled in the US since 2009, many cases go undiagnosed, and screening is now considered cost-effective.
Full answer →Does taking ribavirin for Hepatitis C cause more genetic mutations in the virus?
Yes, ribavirin increases genetic mutations in HCV, as shown by a randomized trial that found higher mutational load and specific nucleotide changes in the virus.
Full answer →How has the rate of Hepatitis C changed among younger adults in the US?
Hepatitis C rates have increased dramatically among younger US adults, driven by the opioid epidemic and injection drug use.
Full answer →All Hepatitis C Articles
- Eight-Week Sofosbuvir-Velpatasvir Matches Twelve-Week Course in Non-Cirrhotic Hepatitis C
- Direct-acting antiviral therapy and diverse viral infections require comprehensive epidemiological and diagnostic strategy review
- Host non-coding RNAs orchestrate antiviral defense and are targeted by viral counter-defense strategies
- Incarceration acts as a structural determinant of health with higher rates of chronic and infectious diseases
- Viral hepatitis infections pose significantly higher risk for liver cancer than smoking-related lung cancer
- Major HCV genotypes G1, G2, and G3 account for 98.02% of infections in FSU regions
- Direct-acting antivirals achieve 89% sustained virologic response in patients with hepatocellular carcinoma and HCV
- Epigallocatechin-3-gallate shows positive therapeutic effects on various digestive system diseases in animal models
- HLA-B*57:01-guided abacavir prescribing is the clearest preventive paradigm from HLA associations
- Chronic HCV infection drives T cell dysfunction, regulatory T cell accumulation, and metabolic defects that persist after viral clearance
- One in six blood donors in Cameroon carries Plasmodium infection, meta-analysis finds
- Narrative review on ICIs in patients with viral infections and solid tumors
- Meta-analysis of 55 studies assesses HCV prevalence trends across Eastern Mediterranean Region populations
- Randomized trial shows ribavirin increases mutational load and specific transition signatures in HCV
- Meta-analysis of 9 studies estimates HCV seroprevalence of 3.63% among African refugees and displaced persons
- Machine learning models predict SVR in comorbid HCV patients treated with sofosbuvir, daclatasvir, and ribavirin in Pakistan
- Global acute hepatitis C incidence declined overall but increased after 2015, analysis shows
- Updated guidance for hepatitis C virus exposure and acute infection in healthcare personnel
- Hepatitis C cases increasing dramatically in US population, especially among younger adults
- CDC Recommends Universal Hepatitis C Screening for Adults and All Pregnant Women
- National trends show rising Hepatitis C and opioid use disorder rates in pregnant women at delivery
- Updated PHS guidelines recommend HIV, HBV, and HCV testing for pediatric transplant candidates under 12
- Hepatitis C treatment patterns examined in insured US adults
- CDC issues hepatitis C testing recommendations for perinatally exposed infants and children
- CDC issues new guidance for completing hepatitis C virus testing
- 8-week glecaprevir/pibrentasvir shows 96.2% SVR12 in acute HCV treatment-naïve adults
- HCV treatment with direct-acting antivirals linked to reduced alcohol use in people who inject drugs